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Summary Seventy-two consecutive patients were eligible for a study of clinical determinants of response and
response duration in small cell lung cancer (SCLC). Pretreatment values of routine laboratory parameters, and
three tumour markers: neuron specific enolase (NSE), carcinoembryonic antigen (CEA), and acidic glyco-
protein (AGP) were measured. Descriptive clinical variables as performance status (PS), extent of disease, age
and sex were also included in the study. All variables were analysed for influence on the type and duration of
response.
The complete remission probability was only related to pretreatment extent of disease. In a multivariate
analysis (Cox) of response duration, only NSE and type of response had significant influence. Consequently,
measurements of NSE before therapy will be useful in future clinical trials on SCLC especially in situations,
where responding patients are submitted to specific treatment strategies.
Remission rates, response duration and survival time are
essential parameters in the assessment of treatment effect in
small cell lung cancer (SCLC).
Increasing interest for identification of factors with influ-
ence on the three parameters has emerged during the latest 10
years. Limited disease (LD) is the most essential factor for a
good prognosis (0sterlind et al., 1983). In addition pretreat-
ment performance status and several biochemical parameters
have been proved to influence the prognosis.
Recently, the neuronal glycolytic enzyme neuron specific
enolase (NSE), has been found in abnormal serum concentra-
tions in more than 75% of patients with SCLC. The concen-
tration of NSE correlates with the extent of disease, but
independent of this relationship NSE in itself contributes to
the prognosis of the patients (J0rgensen et al., 1988), albeit
the prognostic impact of NSE has not been significant in all
investigations (Carney et al., 1982; Akoun et al., 1985;
Gronowitz et al., 1990).
The present investigation was addressed on the role of
NSE as a possible determinant of the probability to obtain
complete remission and of overall remission duration.
Materials and methods
This investigation included a consecutive series of SCLC
patients referred to the Finsen Institute between 1985 and
1987 given protocolled first line chemotherapy for SCLC. All
underwent pretreatment investigations including confirmation
of the histopathologic diagnosis (WHO, 1981), staging in-
cluding abdominal ultrasonography and bilateral iliac crest
biopsies, measurements of biochemical variables, and per-
formance status (PS) according to the WHO criteria (WHO,
1979).
Definitions of response and response duration were in
agreement with the WHO criteria (1979). Patients with
unevaluable disease lesions and patients dying within the first
4 weeks after initiation of chemotherapy were regarded
unevaluable for response and were therefore not included in
this analysis. Patients dying while in remission were censored
on the day of death.
NSE, carcino-embryonic antigen (CEA), and alpha-I-acid
glucoprotein (AGP) were analysed at the Diagnostic
Development Unit, Leeds University, England. NSE was
analysed by the Pharmacia RIA kit, CEA by the Amerwell
CEA-RIA kit (Amersham International plc., Amersham,
UK), and AGP by radial immunodiffusion using antisera
obtained from DAKO A/S, Copenhagen, Denmark. Upper
normal limits for NSE, CEA, and AGP were set to
12.5 ng ml', 5.0 ng ml-', and 1.4 g 1', respectively.
All possible explanatory variables were dichotomised in
order to investigate apparent relationships between the
variables and the possibility ofcomplete remission and remis-
sion duration (CR and PR). The resulting 2 x 2 tables were
tested for statistical significant differences by the chi square
test. Response durations were analysed by life tables and
differences between groups were compared by the log rank
Table I Pretreatment characteristics in patients with SCLC
Age (median, range) LD 64 (41 -72) years
ED 62 (38-73) years
Stage LD 45 pts. 62.5%
ED 27 pts. 37.5%
Liver metast. - 53 pts. 73.6%
+ 19 pts. 26.4%
Bone marrow metast. - 60 pts. 83.3%
+ 12 pts. 16.7%
Performance status 0-1 57 pts. 79.2%
> 1 14 pts. 19.5%
NR 1 Pt. 01.3%
Sex M 50 pts. 69.4%
F 22 pts. 30.6%
LDH _ 450 U1' 39 pts. 54.2%
>450U1' 33 pts. 45.8%
AP _275UI-l 44 pts. 61.1%
>275Ul1' 28 pts. 38.9%
NSE <12.5ngml' 20 pts. 02.8%
> 12.5 ng ml-' 52 pts. 72.2%
CEA <Sngml-' 40 pts. 55.6%
>Sngml-' 32 pts. 44.4%
AGP <1.4gl' 34 pts. 47.2%
>1.4gl-1 38 pts. 52.8%
Sodium > 136 mmol 1- 51 pts. 70.8%
<136mmoll-' 14 pts. 19.5%
NR 9 pts. 09.7%
LD: Limited disease, ED: Extensive disease, M: male, F: female,
LDH: lactate dehydrogenase, AP: alkaline phosphatase, NSE:
neuron specific enolase, CEA: carcinoembyronic antigen, AGP:
acidic glycoprotein, sodium: plasma sodium, NR: not recorded.
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test (Peto et al., 1977). Possible relationships between
pretreatment characteristics and response duration were
analysed by use of Cox's proportional hazards model (Cox,
1972). The BMDP PC program (Berkeley, CA, 1990) was
used for the analyses. A significance level of P <0.05 was
used in all tests.
Table II Influence of
Characteristics
LD
ED
Liver metast. -
Liver metast. +
Bone marrow met. -
Bone marrow met. +
Male
Female
PS <l
PS >1
Age <60
Age >60
LDH <450 U -'
LDH >450 U 1-'
NSE l12.5ngml-'
NSE >12.5ngml-'
CEA < 5.0 ng ml-'
CEA > 5.0 ngml-'
AGP 1.4 g 1'
AGP >1.4gh-'
clinical and biochemical variables on
response
CR rate %
(22/45) 49
(7/27) 26
(25/53) 47
(04/19) 21
(26/60) 43
(03/12) 25
(19/50) 38
(10/22) 45
(24/57) 42
(4/14) 29
(12/33) 36
(17/39) 44
(18/39) 46
(11/33) 33
(8/20) 40
(21/52) 40
(19/40) 48
(10/32) 31
(17/34) 50
(12/38) 32
LD: limited disease, ED: extensive disease, PS:
LDH: lactate dehydrogenase, NSE: neuron spei
carcinoembryonic antigen, AGP: acidic glycoprc
X2
3.70
3.97
1.397
0.35
0.86
0.39
p
0.054
0.046
0.237
0.553
Table III Influence of variables on disease free survival
Median
response LRT LRT
Variable duration 2 p
Extent LD 8 mths. 8.413 0.0037
Response CR 13 mths. 10.128 0.0015
PR 8 mths. 1018 .05
Sex M 9 mths. 0.768 0.3808
F 10 mths.
NSE <12.5ngml' 13 mths. 18.613 0.0001
NSE >12.5Sngml-' 7 mths.
LDH >450UI-1 11 mths. 1.212 0.5457
LDH >450U1 8 mths.
PS 0-1 10 mths. 2.126 0.1448
PS >1 7 mths.
LRT: log rank test, LD: limited disease, ED: extensive disease,
CR: complete response, PR: partial response, M: male, F: female,
NSE: neuron specific enolase, LDH: lactate dehydrogenase, PS:
performance status.
0.353
0.533 Results
1.221 0.269 Seventy-two patients were eligible for the present study.
Patient clinical and biochemical characteristics on entry to
0.00089 0.976 the study are shown in Table I. Median age and range did
not differ significantly, while fraction of PS 0 + 1 was higher
1.951 0.162 in LD than in ED (87% and 72% respectively). The male:
2.531 0.112 female ratio was about 2:1 in both groups. Proportion of
patients with increased values was highest for NSE, all other
performance status, except AGP were below 0.5, lowest for AP.
cific enolase, CEA: CR was obtained in 29 patients with PR in 43 patients.
)tein. Systemic relapse was diagnosed in 64 of included patients,
Response duration (in relation to type of response)
CR
.---- ---PR
Days
Figure 1 Response duration in SCLC. CR: complete response, PR: partial response.
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while six had cerebral relapse. One patient was still alive,
when the study was closed, while another wanted withdrawal
of medication and any follow up until death.
All variables were analysed for influence on the probability
to obtain a complete remission. The CR rates in relation to
various clinical and laboratory pretreatment characteristics
are shown in Table II. Best CR rates were observed in
patients with LD and in patients with normal AGP, while
ED, especially with liver involvement, and PS> 1 carried the
lowest rate. None of the differences, except for liver meta-
stases, were statistically significant, however.
Results of the life table analyses and log rank tests of
relationships between pretreatment characteristics and re-
sponse duration (CR and PR) are summarised in Table III.
Median response duration was 13 and 9 months in CR and
PR respectively (Figure 1). In a separate life table increased
NSE values were further categorised (< 50, >50 ng ml-').
Median response durations were 13, 9 and 7 months (Figure
2).
The results of the Cox analysis are summarised in Table
IV. NSE and type of response were significantly related to
response duration. Extent of disease and PS did not add
significant information and were excluded. Other investigated
pretherapeutic factors carried lower influence. The propor-
tionality assumption was tested for NSE, type of response,
PS, and stage of disease, and was not violated in any of these
four variables. Estimation of response duration from the Cox
analysis revealed four separate classes with different response
time (Figure 3).
Discussion
Induction and maintenance of a disease remission are essen-
tial in treatment of cancer. Knowledge of clinical deter-
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Table IV Cox's proportional hazard regression analysis of 72 pts
having a CR or a PR
Regression
coefficient SE P RR
Response (CR vs PR) 1.102 0.266 0.001 3.0
NSE 0.840 0.182 0.001 2.3
RR: relative risk.
minants may thus be helpful in the evaluation of treatment
response and improve the understanding of clinical
variability.
Baseline extent of disease was in our investigation alone an
initial response determinant of CR. This importance of
extent of disease has previously been stressed. In each of
three prognostic groups a higher response rate was found in
LD compared with ED (Souhami et al., 1985). In an investi-
gation, stratified for stage of disease, sex was significantly
related to CR probability in both stages, favouring women.
Performance status possessed significant relation in ED only
(Ostelind et al., 1987).
In our investigation neither pretreatment NSE nor LDH
were response determinants. This lack of critical reference to
NSE is refound in other investigations. Akoun et al. (1985)
found no significant correlation between initial NSE level
and response to chemotherapy by the end of the third month
ofcytostatic treatment given to 41 SCLC patients. Among 38
LD patients, there was no difference in the response rate
between those who initially had a normal NSE and those
who presented with high NSE. In 56 ED patients no
significant correlation was found between initial serum NSE
level and response to therapy (Carney et al., 1982). LDH was
not related to the probability of CR in this investigation
ation (in relation to NSE) - NSE < 12.6
......... NSE 12.5-50
NSE > 50
730
Days
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Figure 3 Response duration in SCLC. CR: complete response, PR: partial response, NSE: neuron specific enolase.
albeit such a relationship later was proven in two large series
from Copenhagen (0sterlind et al., 1987) and Toronto (Sag-
man et al., 1991), respectively. NSE was not included in these
studies, but a close correlation between LDH and NSE has
been shown (J0rgensen et al., 1988).
In numerous investigations (Carney et al., 1982; Akoun et
al., 1985; Cooper et al., 1987; J0rgensen et al., 1989;
Gronowitz et al., 1990) a close correlation between disease
extent and NSE was found. The lack of influence of NSE on
probability for CR vs that of a PR may partly be caused by
the extremely difficult distinction between the responses. This
is stressed by the understanding of SCLC as a disseminated
disease at presentation with early potential for metastatic
dissemination and the stage as a tool facilitating treatment
strategy (Idhe et al., 1981).
Our results corroborate the well established experience that
extent of disease has major influence on the probability of
CR. The new knowledge derived from this investigation is
that NSE, in addition to type of response (CR vs PR), are
important determinants of response duration. Consequently,
NSE is a relevant laboratory measurement and should be
included in future SCLC treatment trials, especially if a
secondary randomisation of responding patients should take
place. It might aid understanding biological variability and
be helpful for comparison of treatment results.
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